Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Objective: To investigate the addition of prophylactic G-CSF to each weekly paclitaxel/carboplatin course in patients with recurrent platinum-resistant ovarian (OC), or recurrent or advanced endometrial (EC) or cervical carcinoma (CC).
Methods: 108 patients were enrolled i.e. 36 in each cohort. Eighteen courses of paclitaxel (60 mg/m(2)) and carboplatin (AUC 2.7) were administered weekly. G-CSF (filgrastim) was given to all patients on day 5 (and if needed on day 6).
Results: For patients with OC, 91% had platinum-resistant and 9% platinum-refractory disease. Median number of prior chemotherapy lines was 3 for OC, 1 for EC, and 1 for CC. Grade 3-4 neutropenia was observed in 34% of patients (95% CI: 26%-44%, P<0,0001) (OC 29%, EC 36%, CC 38%). This is lower compared to historical data in all cohorts (84%). Confirmed sepsis was observed in 5%, grade 3-4 thrombocytopenia in 41%, grade 2-3 peripheral neuropathy in 17% of patients. In 71% of patients dose was delayed. Dose reduction was necessary for carboplatin in 47% and paclitaxel in 18% of patients. ORR was 51% (OC 48%, EC 45%, CC 58%). Median (95% CI) PFS and OS was 7.1 (5.1-8.1) and 12.7 (10.2-16.3) months, respectively (OC 7 and 13, EC 6 and 19, CC 6 and 14).
Conclusion: Weekly paclitaxel/carboplatin with G-CSF is an effective treatment with acceptable toxicity in patients with platinum-resistant or platinum-refractory OC, advanced or recurrent EC and CC. The incidence of grade 3-4 neutropenia is lower with the addition of weekly G-CSF compared with earlier studies without routine use of prophylactic G-CSF.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ygyno.2015.05.042 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Continuous remission of single-mode therapy with pembrolizumab plus chemotherapy in locally advanced hypopharyngeal carcinoma: a case report.
Front Immunol
June 2025
Department of Otorhinolaryngology-Head and Neck Surgery, Changhai Hospital, Naval Medical University, Shanghai, China.
Hypopharyngeal carcinoma, one of the common malignant tumors of the head and neck, is associated with high tumor aggressiveness, early cervical lymph node metastasis, and a poor prognosis. Neoadjuvant immunotherapy has been gradually introduced to treat locally advanced head and neck squamous cell carcinoma (LA-HNSCC), including hypopharyngeal carcinoma. Despite survival benefit advantages, there is no consensus on the treatment mode after neoadjuvant immunotherapy, especially for patients achieving a complete response (CR).
View Article and Find Full Text PDFPancreatic metastasis from cervical cancer: A case report and literature review.
Oncol Lett
July 2025
Department of Radiation Oncology, Peking Union Medical College Hospital Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, P.R. China.
Cervical cancer metastasis to the pancreas is rare, and the clinical manifestations are variable and contingent upon the location of the metastasis. Consequently, certain patients may be overlooked due to the absence of overt clinical symptoms. Nevertheless, there is no universally accepted treatment protocol for such patients.
View Article and Find Full Text PDFSurvival Outcomes and Predictive Factors to Evaluate the Efficacy of Neoadjuvant Chemoradiation in Carcinoma Esophagus: An Institutional Experience from India.
Gulf J Oncolog
September 2024
Department of Radiation Oncology, Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, India.
Aim & Objectives: Although NCRT (Neoadjuvant Chemo Radiation Therapy) followed by surgery demonstrates an increase in overall survival (OS) in locally advanced operable esophageal cancer, there is a lack of a reliable predictive factor to identify patients who are more likely to be affected by treatment toxicities or natural history of the disease. In this study, we have studied various indices like pre-treatment serum albumin, hemoglobin, Neutrophil to Lymphocyte Ratio (NLR), Platelet to Lymphocyte Ratio (PLR), Platelet to Albumin Ratio (PAR), Systemic Immune Index (SII) as independent prognostic factors in esophageal cancer, with respect to the outcomes and tumor response. Material & Methods: A total of 83 patients of esophageal cancer who were treated with Neoadjuvant Chemoradiation from 2016-2021 were evaluated in this study.
View Article and Find Full Text PDFPhase II Study to Evaluate the Safety and Efficacy of Neoadjuvant Chemotherapy with Weekly Paclitaxel and Carboplatin Followed by Radical Chemoradiation in Locally Advanced Cervical Cancer in Egyptian Population.
Asian Pac J Cancer Prev
April 2025
Clinical Oncology and Nuclear Medicine Department, Faculty of Medicine, Ain Shams University, El Qalybia, Cairo, Egypt.
Background: Since 1999, platinum based chemoradiation (CRT) is the standard treatment for locally advanced cervical cancer patients, but the estimated increase in overall survival (OS) over a 5-year period was only 6% in patients treated with CRT versus radiotherapy alone.There have been no additional developments in the treatment of locally advanced cervical cancer(LACC) patients since CRT introduction and approximately 30-40% of those patients failed to achieve complete response to CRT. Therefore, alternative approaches are needed to improve the outcome for such patients.
View Article and Find Full Text PDFPharmacoeconomic Analysis of Treating Gynecological Cancer with Different Regimens Using the Cheapest and Costliest Brand of Drugs Marketed in India.
J Obstet Gynaecol India
December 2024
Research Unit, Mangalore Institute of Oncology, Pumpwell, Mangalore, Karnataka 75002 India.
Article Synopsis
- The study aimed to analyze the cost differences of treating gynaecological cancer in India by comparing the prices of the most and least expensive branded drugs available.
- The researchers conducted a conventional pharmacoeconomic study, assessing both branded drugs and those from Jan Aushadhi stores to determine cost variations and potential savings.
- Findings revealed significant cost disparities, particularly with certain regimens, indicating that cheaper alternatives could lead to substantial savings for patients without sacrificing treatment options.